Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction CEP chemotherapy plus chemoradiotherapy versus chemoradiotherapy alone for locally advanced nasopharyngeal carcinoma
ACTRN12609000730202Phase 2Completed
- Sponsor
- HeCOG
- Start
- Oct 2003
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin, epirubicin and paclitaxel in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by HeCOG. Primary endpoint: Overall response rate. Started Oct 2003; status: completed.
02
Drugs
cisplatinepirubicinpaclitaxel
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ACTRN12609000730202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000730202.